Tovetumab
Monoclonal antibody
From Wikipedia, the free encyclopedia
Tovetumab is an anti-PDGFRa monoclonal antibody designed for the treatment of cancer.[1] It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer.[2] Development was discontinued in 2013.[3][4]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | PDGFRA |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6400H9906N1726O2002S54 |
| Molar mass | 144792.97 g·mol−1 |
This drug was developed by MedImmune, LLC.[citation needed]
